Ann C. Mladek

2.5k total citations
41 papers, 1.5k citations indexed

About

Ann C. Mladek is a scholar working on Molecular Biology, Genetics and Oncology. According to data from OpenAlex, Ann C. Mladek has authored 41 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Molecular Biology, 25 papers in Genetics and 14 papers in Oncology. Recurrent topics in Ann C. Mladek's work include Glioma Diagnosis and Treatment (25 papers), DNA Repair Mechanisms (9 papers) and Brain Metastases and Treatment (9 papers). Ann C. Mladek is often cited by papers focused on Glioma Diagnosis and Treatment (25 papers), DNA Repair Mechanisms (9 papers) and Brain Metastases and Treatment (9 papers). Ann C. Mladek collaborates with scholars based in United States, United Kingdom and Chile. Ann C. Mladek's co-authors include Jann N. Sarkaria, Brett L. Carlson, Paul A. Decker, Mark A. Schroeder, Gaspar J. Kitange, Raúl Urrutia, Shiv K. Gupta, Wenting Wu, Patrick T. Grogan and Tiffany Cook and has published in prestigious journals such as Journal of Biological Chemistry, Analytical Chemistry and JNCI Journal of the National Cancer Institute.

In The Last Decade

Ann C. Mladek

41 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ann C. Mladek United States	20	1000	597	473	282	209	41	1.5k
Juyoun Jin South Korea	19	758 0.8×	478 0.8×	646 1.4×	395 1.4×	153 0.7×	30	1.5k
Theodore Nicolaides United States	25	1.0k 1.0×	811 1.4×	276 0.6×	313 1.1×	253 1.2×	56	1.8k
Jenny L. Pokorny United States	13	719 0.7×	496 0.8×	405 0.9×	236 0.8×	151 0.7×	21	1.2k
Christine Toulas France	29	1.3k 1.3×	462 0.8×	561 1.2×	669 2.4×	163 0.8×	59	2.0k
Hiroyuki Momota Japan	19	846 0.8×	669 1.1×	246 0.5×	357 1.3×	131 0.6×	39	1.5k
Steven N. Quayle United States	17	1.0k 1.0×	359 0.6×	557 1.2×	300 1.1×	224 1.1×	37	1.5k
Felix Zeppernick Germany	17	609 0.6×	290 0.5×	691 1.5×	384 1.4×	185 0.9×	40	1.6k
Luca Persano Italy	26	1.1k 1.1×	572 1.0×	591 1.2×	676 2.4×	142 0.7×	55	2.0k
Caroline Delmas France	22	794 0.8×	343 0.6×	408 0.9×	433 1.5×	110 0.5×	37	1.4k
Giannicola Genovese United States	17	1.1k 1.1×	238 0.4×	497 1.1×	331 1.2×	304 1.5×	34	1.6k

Countries citing papers authored by Ann C. Mladek

Since Specialization

Citations

This map shows the geographic impact of Ann C. Mladek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ann C. Mladek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ann C. Mladek more than expected).

Fields of papers citing papers by Ann C. Mladek

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ann C. Mladek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ann C. Mladek. The network helps show where Ann C. Mladek may publish in the future.

Co-authorship network of co-authors of Ann C. Mladek

This figure shows the co-authorship network connecting the top 25 collaborators of Ann C. Mladek. A scholar is included among the top collaborators of Ann C. Mladek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ann C. Mladek. Ann C. Mladek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhang, Wenjuan, Rachael A. Vaubel, Ann C. Mladek, et al.. (2023). Delivery versus Potency in Treating Brain Tumors: BI-907828, a MDM2-p53 Antagonist with Limited BBB Penetration but Significant In Vivo Efficacy in Glioblastoma. Molecular Cancer Therapeutics. 23(1). 47–55. 5 indexed citations

Stopka, Sylwia A., Ju‐Hee Oh, Ann C. Mladek, et al.. (2023). WSD-0922, a novel brain-penetrant inhibitor of epidermal growth factor receptor, promotes survival in glioblastoma mouse models. Neuro-Oncology Advances. 5(1). vdad066–vdad066. 4 indexed citations

Kizilbash, Sani H., Shiv K. Gupta, Karen E. Parrish, et al.. (2021). In Vivo Efficacy of Tesevatinib in EGFR -Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling. Molecular Cancer Therapeutics. 20(6). 1009–1018. 10 indexed citations

Burgenske, Danielle M., Ann C. Mladek, Katrina K. Bakken, et al.. (2021). Quantitative Analysis of Tyrosine Phosphorylation from FFPE Tissues Reveals Patient-Specific Signaling Networks. Cancer Research. 81(14). 3930–3941. 19 indexed citations

Gampa, Gautham, Minjee Kim, Afroz S. Mohammad, et al.. (2019). Brain Distribution and Active Efflux of Three panRAF Inhibitors: Considerations in the Treatment of Melanoma Brain Metastases. Journal of Pharmacology and Experimental Therapeutics. 368(3). 446–461. 16 indexed citations

Gupta, Shiv K., Emily J. Smith, Ann C. Mladek, et al.. (2019). PARP Inhibitors for Sensitization of Alkylation Chemotherapy in Glioblastoma: Impact of Blood-Brain Barrier and Molecular Heterogeneity. Frontiers in Oncology. 8. 670–670. 59 indexed citations

Kizilbash, Sani H., Shiv K. Gupta, Kenneth Tou En Chang, et al.. (2017). Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma. Molecular Cancer Therapeutics. 16(12). 2735–2746. 60 indexed citations

Mamo, Tewodros, Ann C. Mladek, Shiv K. Gupta, et al.. (2017). Inhibiting DNA-PKCS radiosensitizes human osteosarcoma cells. Biochemical and Biophysical Research Communications. 486(2). 307–313. 27 indexed citations

Laramy, Janice K., Minjee Kim, Shiv K. Gupta, et al.. (2017). Heterogeneous Binding and Central Nervous System Distribution of the Multitargeted Kinase Inhibitor Ponatinib Restrict Orthotopic Efficacy in a Patient-Derived Xenograft Model of Glioblastoma. Journal of Pharmacology and Experimental Therapeutics. 363(2). 136–147. 21 indexed citations

10.

Kitange, Gaspar J., Ann C. Mladek, Mark A. Schroeder, et al.. (2016). Retinoblastoma Binding Protein 4 Modulates Temozolomide Sensitivity in Glioblastoma by Regulating DNA Repair Proteins. Cell Reports. 14(11). 2587–2598. 53 indexed citations

11.

Gupta, Shiv K., Sani H. Kizilbash, Brett L. Carlson, et al.. (2015). Delineation ofMGMTHypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma. JNCI Journal of the National Cancer Institute. 108(5). djv369–djv369. 93 indexed citations

12.

Mladek, Ann C., Roger M. Phillips, Mikko Gynther, et al.. (2014). Evaluation of Novel Imidazotetrazine Analogues Designed to Overcome Temozolomide Resistance and Glioblastoma Regrowth. Molecular Cancer Therapeutics. 14(1). 111–119. 19 indexed citations

13.

Gupta, Shiv K., Ann C. Mladek, Brett L. Carlson, et al.. (2014). Discordant In Vitro and In Vivo Chemopotentiating Effects of the PARP Inhibitor Veliparib in Temozolomide-Sensitive versus -Resistant Glioblastoma Multiforme Xenografts. Clinical Cancer Research. 20(14). 3730–3741. 57 indexed citations

14.

Cen, Ling, Brett L. Carlson, Jenny L. Pokorny, et al.. (2013). Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models. Neuro-Oncology. 15(6). 735–746. 24 indexed citations

15.

Kitange, Gaspar J., Ann C. Mladek, Brett L. Carlson, et al.. (2012). Inhibition of Histone Deacetylation Potentiates the Evolution of Acquired Temozolomide Resistance Linked to MGMT Upregulation in Glioblastoma Xenografts. Clinical Cancer Research. 18(15). 4070–4079. 125 indexed citations

16.

Carlson, Brett L., Patrick T. Grogan, Ann C. Mladek, et al.. (2009). Radiosensitizing Effects of Temozolomide Observed in vivo only in a Subset of O6-Methylguanine-DNA Methyltransferase Methylated Glioblastoma Multiforme Xenografts. International Journal of Radiation Oncology*Biology*Physics. 75(1). 212–219. 75 indexed citations

17.

Kitange, Gaspar J., Brett L. Carlson, Ann C. Mladek, et al.. (2008). Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model. Journal of Neuro-Oncology. 92(1). 23–31. 74 indexed citations

18.

Sarkaria, Jann N., Steven E. Schild, Patrick T. Grogan, et al.. (2007). Phase I Trial of Sirolimus Combined with Radiation and Cisplatin in Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 2(8). 751–757. 39 indexed citations

19.

Rao, Ravi D., et al.. (2005). Disruption of Parallel and Converging Signaling Pathways Contributes to the Synergistic Antitumor Effects of Simultaneous mTOR and EGFR Inhibition in GBM Cells. Neoplasia. 7(10). 921–929. 78 indexed citations

20.

Cook, Tiffany, et al.. (1998). Molecular Cloning and Characterization of TIEG2Reveals a New Subfamily of Transforming Growth Factor-β-inducible Sp1-like Zinc Finger-encoding Genes Involved in the Regulation of Cell Growth. Journal of Biological Chemistry. 273(40). 25929–25936. 165 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact